Recent Finacing
Recent Raise
Elixiron develops cancer, neurological, and inflammatory therapeutics via reverse‑translational immunotherapy, operating R&D and clinical programs in San Francisco, Taipei, and Shanghai with oral CSF1R and antibody pipeline assets.
